FiscalNote Removed From NYSE After Delisting

FiscalNote’s listing on the New York Stock Exchange was terminated this week following a formal delisting notice, a development that sent the company’s quoted shares tumbling by more than 70% intraday (Yahoo Finance, Mar 29, 2026). The delisting follows a sustained failure to meet NYSE continued-listing criteria, most notably the minimum $1.00 per-share price standard outlined in the NYSE Listed Company Manual (NYSE). Under the exchange’s procedures, companies receive notification and generally have a 10-business-day window to request review or a hearing to appeal staff determinations (NYSE Listed Company Manual). The market reaction was immediate: liquidity evaporated, block trades widened materially, and broker-dealers flagged heightened counterparty and settlement risk for positions in the name.

Context

FiscalNote’s removal from the NYSE represents the final operational step after a multi-month compliance trajectory in which the company failed to cure recurrent listing deficiencies. The NYSE’s $1.00 minimum price standard — commonly invoked in delisting actions — is one of several quantitative thresholds (others include aggregate market value, shareholders’ equity and timely periodic filings) that exchanges monitor; failure on any material standard can trigger a delisting process (NYSE Listed Company Manual). The delisting notice reported by Yahoo Finance on Mar 29, 2026 set in motion procedural safeguards for the company: an initial notification, a potential staff review, and the possibility of a hearing if the issuer files within the standard 10-business-day appeal period (Yahoo Finance; NYSE).

The market context is relevant. Smaller-cap, late-stage technology and data-analytics companies have disproportionately exhibited price volatility since 2024 as investor focus shifted from top-line growth to cash-burn metrics and governance. Public filings show that FiscalNote’s trading volumes were extremely low relative to the average NYSE listing in recent quarters, which exacerbated price moves once the delisting notice became public. For institutional holders, this combination of thin liquidity and a forced shift to over-the-counter trading pathways increases transaction costs and operational friction, with implications for mark-to-market practices and valuation protocols.

Finally, the timing of the exchange action matters from an operational perspective. A delisting determination does not always mean immediate cessation of quoted trading on regulated markets; there is a sequence of notices, cure periods and appeals during which the company can seek to regain compliance or negotiate continued access. The chronology anchored by the Mar 29, 2026 press reports establishes where FiscalNote sits in that sequence, and that standing informs counterparty decisions by dealers, prime brokers and funds with custody rules that restrict OTC exposure.

Data Deep Dive

Three specific data points frame the technical dimensions of this action. First, the delisting notice and the market reaction were reported on Mar 29, 2026 by Yahoo Finance (source: Yahoo Finance, Mar 29, 2026), which documented a greater-than-70% intraday decline in quoted share value concurrent with the NYSE notice. Second, the NYSE continued-listing standard for minimum per-share price is $1.00; falling below that threshold for a prescribed period typically precipitates review by exchange staff (source: NYSE Listed Company Manual). Third, the exchange’s process allows an issuer 10 business days to request a review or a hearing after notification, a procedural window that companies frequently use to prepare a cure plan or to marshal supporting evidence (source: NYSE Listed Company Manual).

Beyond those regulatory data points, trading metrics on the session indicate a marked expansion in bid-ask spreads and a collapse in displayed liquidity. In practical terms, market-makers widened quotes as they reassessed inventory risk and the probability of an ultimate transfer to an OTC venue. Settlement risk spiked; clearing firms flagged positions and some prime brokers placed temporary restrictions on financing against the security. For institutions with sizable exposure, typical mitigants — risk-limited block trades, accelerated unwinds, or netting against other positions — were constrained by counterparties’ risk limits.

Relative performance comparisons are instructive. FiscalNote’s price trajectory over the past 12 months diverged sharply from both broad benchmarks and select sector peers. Where large-cap indices stayed range-bound, the company’s quoted price declined materially as governance and liquidity concerns compounded operational performance questions. That divergence underlines the asymmetric risk profile of small-cap, information-services names during episodes of governance scrutiny.

Sector Implications

FiscalNote’s delisting is not an isolated regulatory curiosity; it fits into a pattern affecting small-cap technology and data-analytics providers whose public-market business models rely on recurring revenue and high growth assumptions. For the sector, delistings raise the bar on corporate governance, transparency and balance-sheet resilience — institutional investors newly prioritize metrics such as free cash flow generation, gross margin stability and customer-concentration limits. In practical terms, funds that allocate to small-cap tech names will likely increase due diligence intensity and expand covenant checks in private-equity-style operational reviews.

Comparisons with peers that retained exchange listings show a bifurcation: companies that maintained per-share prices above $1.00 and delivered consistent filings preserved institutional coverage and trading liquidity, while firms that trailed on those fronts experienced accelerated sell-offs and skeptical analyst coverage. The net effect for the sector is a reorientation toward capital efficiency; boards and management teams face market incentives to fortify liquidity (cash buffers or committed facilities) to avoid exchange-triggered crises.

Equally important are implications for market structure and secondary trading venues. A move to OTC markets often reduces transparency and raises execution costs; for corporate stakeholders, that can impair employee compensation programs based on equity and complicate M&A prospects. Vendors, clients and partners may also interpret a delisting as a signal of elevated operational risk, which can have knock-on effects for commercial contracts and partner confidence.

Risk Assessment

From an institutional perspective, the immediate risks include settlement and counterparty exposure, valuation uncertainty, and the potential for continued volatile mark-to-market losses. Custodians and trustees may invoke gating provisions in custody agreements that either restrict trading or require enhanced collateralization for positions in delisted names. Those operational controls can amplify forced sales, creating a feedback loop that further depresses price.

Legal and compliance risks are also salient. Delisting often triggers covenant tests in lending agreements, accelerations provisions and potential litigation risk from shareholders who may allege disclosure deficiencies. For private investors in subsequent recapitalizations, the delisting history is a material event that affects transaction pricing and deal structure; potential acquirers place a premium discount on resolving legacy governance or financial-reporting issues.

Finally, reputational risk can be decisive. Management teams must balance transparency with the need to avoid information cascades that accelerate outflows. In many delisting scenarios, the company’s ability to marshal a credible cure plan within the exchange’s procedural window — and to communicate that plan effectively to stakeholders — materially influences the end-state severity.

Fazen Capital Perspective

Fazen Capital views FiscalNote’s delisting as a case study in the limits of narrative-driven valuations when operational and liquidity metrics weaken. While headline growth metrics can sustain interest, institutional allocations increasingly require demonstrable margin improvement and balance-sheet durability. A contrarian read is that delisting events compress risk premia to potentially mispriced levels for sophisticated, operationally oriented buyers; however, execution complexity and information asymmetry typically justify cautious valuation discounts.

From a portfolio-construction standpoint, the event underscores the value of pre-trade operational checks — including liquidity stress tests and contractual reviews — that anticipate regulatory triggers. Firms that can deploy capital selectively post-delisting may find opportunities, but such plays demand specialized capabilities: legal diligence, OTC market execution expertise and contingency planning for employee-equity structures. Fazen Capital’s research links on governance and market structure provide further context for investors recalibrating exposure governance insights and market-structure analysis.

Outlook

In the near term, FiscalNote’s path depends on whether management files for a hearing within the NYSE’s procedural window and whether a credible cure plan can be executed that addresses the exchange’s cited deficiencies. If no appeal or cure is forthcoming, an orderly migration to OTC trading is likely, with attendant higher spreads and reduced institutional participation. Over the medium term, recovery of public-market status would likely require a combination of capital infusion, operational turnaround and improved disclosure — a sequence that historically takes 12–24 months for companies that successfully relist.

For the sector, expect increased scrutiny on balance-sheet metrics and heightened sensitivity to per-share price thresholds that can trigger exchange actions. Boards and management teams will likely prioritize disclosure cadence and liquidity contingency planning to mitigate the probability of similar outcomes. On the regulatory front, exchanges may also refine guidance to help issuers navigate compliance timelines and cure protocols.

Bottom Line

FiscalNote’s NYSE removal crystallizes the intersection of liquidity risk, governance scrutiny and exchange rules; the operational and valuation consequences for stakeholders are immediate and material. Investors and counterparties must treat delisting events as multifaceted operational risks that demand coordinated legal, trading and governance responses.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

FAQ

Q: What immediate steps can a company take after receiving an NYSE delisting notice?

A: The issuer can (1) request a review or hearing within the 10-business-day window provided by the NYSE, (2) propose a remedial plan to cure the deficiency — for example, reverse stock splits to rectify a sub-$1 price — and (3) engage with market-makers and advisors to preserve liquidity during the process. Those steps buy time and can stave off immediate migration to OTC trading if executed credibly (source: NYSE Listed Company Manual).

Q: How does a move from the NYSE to OTC affect institutional holders operationally?

A: Migration to OTC usually reduces display liquidity and increases bid-ask spreads, complicates settlement and prime-broker financing, and may trigger custodial or fund-level restrictions that limit continued holdings. Such operational frictions can force larger reporting changes in NAV and potentially require accelerated liquidation or revaluation steps depending on mandate constraints.

Q: Are delistings more frequent now than historically?

A: Exchange activity varies cyclically, but increased market volatility and the re-rating of growth companies since 2024 have coincided with a higher incidence of delisting notifications among small-cap technology names. Institutions should track sector-specific delisting trends as part of their risk monitoring frameworks; for practical guidance see Fazen Capital’s market-structure brief here.